QR-Code

Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial

Background: Berotralstat is a once-daily oral inhibitor of plasma kallikrein for the prophylaxis of hereditary angioedema (HAE) in patients ≥12 years. APeX-J aimed to evaluate the efficacy and safety of berotralstat in Japan. Methods: APeX-J was a Phase III trial comprising 3 parts (NCT03873116). Pa...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Daisuke Honda, MD, PhD, Michihiro Hide, MD, PhD, Tomoo Fukuda, MD, PhD, Keisuke Koga, MD, PhD, Eishin Morita, MD, PhD, Shinichi Moriwaki, MD, Yoshihiro Sasaki, MD, PhD, Yusuke Suzuki, MD, PhD, Phil Collis, PhD, Douglas T. Johnston, DO, Dianne Tomita, MPH, Bhavisha Desai, PharmD, Isao Ohsawa, MD, PhD
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2024-03-01
Schriftenreihe:World Allergy Organization Journal
Schlagworte:
Angioedemas
Hereditary
Berotralstat
Japan
Plasma kallikrein
Quality of life
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S1939455124000139
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge